{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:29:41Z","timestamp":1790033381946,"version":"4.0.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Otolaryngology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.amjoto.2025.104646","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T11:42:59Z","timestamp":1745235779000},"page":"104646","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Research progress of anti-IGE treatment for allergic rhinitis"],"prefix":"10.1016","volume":"46","author":[{"given":"Rongrong","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anchi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.amjoto.2025.104646_bb0005","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.alit.2022.11.003","article-title":"Executive summary: Japanese guidelines for allergic rhinitis 2020","volume":"72","author":"Okano","year":"2023","journal-title":"Allergol Int"},{"issue":"4","key":"10.1016\/j.amjoto.2025.104646_bb0010","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/alr.23090","article-title":"International consensus statement on allergy and rhinology: allergic rhinitis - 2023","volume":"13","author":"Wise","year":"2023","journal-title":"Int Forum Allergy Rhinol."},{"issue":"1","key":"10.1016\/j.amjoto.2025.104646_bb0015","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12094","article-title":"Omalizumab is effective in the preseasonal treatment of seasonal allergic rhinitis","volume":"12","author":"Zhang","year":"2022","journal-title":"Clin Transl Allergy"},{"issue":"1","key":"10.1016\/j.amjoto.2025.104646_bb0020","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41572-020-00227-0","volume":"6","author":"Bousquet","year":"2020","journal-title":"Allergic rhinitis Nat Rev Dis Primers"},{"issue":"11","key":"10.1016\/j.amjoto.2025.104646_bb0025","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/alr.22827","article-title":"Impact of omalizumab on pollen-induced seasonal allergic rhinitis: an observational study in clinical practice","volume":"11","author":"Hirano","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.amjoto.2025.104646_bb0030","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2147\/JAA.S288952","article-title":"Effectiveness and response predictors of Omalizumab in treating patients with seasonal allergic rhinitis: a real-world study","volume":"14","author":"Ma","year":"2021","journal-title":"J Asthma Allergy"},{"issue":"1","key":"10.1016\/j.amjoto.2025.104646_bb0035","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41392-023-01344-4","article-title":"Pathogenesis of allergic diseases and implications for therapeutic interventions","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"10.1016\/j.amjoto.2025.104646_bb0040","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/j.1398-9995.2008.01824.x","article-title":"Geographical distribution of atopic rhinitis in the European Community respiratory health survey I","volume":"63","author":"Bousquet","year":"2008","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.amjoto.2025.104646_bb0045","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jdcr.2020.01.002","article-title":"Increasing evidence for omalizumab in the treatment of bullous pemphigoid","volume":"6","author":"Lonowski","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"1","key":"10.1016\/j.amjoto.2025.104646_bb0050","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamapediatrics.2019.4476","article-title":"Treatment effect of Omalizumab on severe pediatric atopic dermatitis: the ADAPT randomized clinical trial","volume":"174","author":"Chan","year":"2020","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.amjoto.2025.104646_bb0055","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4137\/CCRPM.S7793","article-title":"Omalizumab: clinical use for the management of asthma","volume":"6","author":"Thomson","year":"2012","journal-title":"Clin Med Insights Circ Respir Pulm Med"},{"issue":"4","key":"10.1016\/j.amjoto.2025.104646_bb0060","doi-asserted-by":"crossref","first-page":"665","DOI":"10.4049\/jimmunol.2101081","article-title":"Peripheral CD23(hi)\/IgE(+) Plasmablasts secrete IgE and correlate with allergic disease severity","volume":"209","author":"Simonin","year":"2022","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.amjoto.2025.104646_bb0065","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.3390\/biomedicines10102486","article-title":"Allergic rhinitis: pathophysiology and treatment focusing on mast cells","volume":"10","author":"Zoabi","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.amjoto.2025.104646_bb0070","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.839011","article-title":"Omalizumab and IgE in the control of severe allergic asthma","volume":"13","author":"Gon","year":"2022","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.amjoto.2025.104646_bb0075","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/00063030-200822030-00005","article-title":"Omalizumab: a review of its use in the treatment of allergic asthma","volume":"22","author":"Plosker","year":"2008","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.amjoto.2025.104646_bb0080","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41467-019-13815-w","article-title":"The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab","volume":"11","author":"Gasser","year":"2020","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.amjoto.2025.104646_bb0085","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/all.14221","article-title":"Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI guidelines - recommendations on the use of biologicals in severe asthma","volume":"75","author":"Agache","year":"2020","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.amjoto.2025.104646_bb0090","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13052-019-0737-4","article-title":"Omalizumab and mepolizumab in the landscape of biological therapy for severe asthma in children: how to choose","volume":"45","author":"Giovannini","year":"2019","journal-title":"Ital J Pediatr"},{"issue":"6","key":"10.1016\/j.amjoto.2025.104646_bb0095","first-page":"501","article-title":"Omalizumab for the treatment of allergic rhinitis: a systematic review and meta-analysis","volume":"59","author":"Tsabouri","year":"2021","journal-title":"Rhinology"},{"issue":"1","key":"10.1016\/j.amjoto.2025.104646_bb0100","doi-asserted-by":"crossref","first-page":"42","DOI":"10.4193\/Rhin17.139","article-title":"Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together-a real life study","volume":"56","author":"Bidder","year":"2018","journal-title":"Rhinology"},{"issue":"2","key":"10.1016\/j.amjoto.2025.104646_bb0105","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jaci.2019.05.019","article-title":"Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort","volume":"145","author":"Namazy","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.amjoto.2025.104646_bb0110","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jaci.2020.08.039","article-title":"Determinants of omalizumab dose-related efficacy in oral immunotherapy: evidence from a cohort of 181 patients","volume":"147","author":"Azzano","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.amjoto.2025.104646_bb0115","series-title":"StatPearls [Internet]","article-title":"Omalizumab. [Updated 2023 Aug 17]","author":"Kumar","year":"2025"},{"issue":"8","key":"10.1016\/j.amjoto.2025.104646_bb0120","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/j.jaip.2020.03.033","article-title":"Treatment benefit with Omalizumab in children by indicators of asthma severity","volume":"8","author":"Szefler","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.amjoto.2025.104646_bb0125","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s12016-015-8490-y","article-title":"Off-label uses of Omalizumab","volume":"50","author":"El-Qutob","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"10.1016\/j.amjoto.2025.104646_bb0130","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.amjoto.2025.104646_bb0135","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2332\/allergolint.55.379","article-title":"Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis","volume":"55","author":"Okubo","year":"2006","journal-title":"Allergol Int"},{"issue":"3","key":"10.1016\/j.amjoto.2025.104646_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2014.02.001","article-title":"Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials","volume":"2","author":"Tsabouri","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.amjoto.2025.104646_bb0145","first-page":"116","article-title":"Omalizumab reduces allergic rhinitis symptoms due to Japanese cedar pollen by improving eosinophilic inflammation","volume":"63","author":"Hirano","year":"2025","journal-title":"Rhinology"},{"key":"10.1016\/j.amjoto.2025.104646_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110623","article-title":"The ratio of total IgE level at week 16 to baseline significantly correlated with the clinical response to omalizumab in moderate to severe allergic rhinitis patients","volume":"122","author":"Zhao","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.amjoto.2025.104646_bb0155","article-title":"Prevention of omalizumab for seasonal allergic rhinoconjunctivitis: a retrospective cohort study","volume":"13","author":"Tang","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.amjoto.2025.104646_bb0160","doi-asserted-by":"crossref","first-page":"152","DOI":"10.4193\/Rhin16.314","article-title":"The effect of systemic treatments on periostin expression reflects their interference with the eosinophilic inflammation in chronic rhinosinusitis with nasal polyps","volume":"55","author":"De Schryver","year":"2017","journal-title":"Rhinology"},{"issue":"12","key":"10.1016\/j.amjoto.2025.104646_bb0165","first-page":"1111","article-title":"Omalizumab in severe asthma: effect on Oral corticosteroid exposure and remodeling","volume":"83","author":"Domingo","year":"2023","journal-title":"A Randomized Open-Label Parallel Study Drugs"},{"issue":"9","key":"10.1016\/j.amjoto.2025.104646_bb0170","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1016\/j.jaip.2020.04.068","article-title":"Add-on Omalizumab for inadequately controlled severe Pollinosis despite standard-of-care: a randomized study","volume":"8","author":"Okubo","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.amjoto.2025.104646_bb0175","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.imlet.2020.08.002","article-title":"Long-term omalizumab efficacy in allergic rhinitis","volume":"227","author":"Cavaliere","year":"2020","journal-title":"Immunol Lett"},{"issue":"2","key":"10.1016\/j.amjoto.2025.104646_bb0180","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.alit.2017.07.009","article-title":"Omalizumab for hypersensitive reaction to seminal plasma: a case report","volume":"67","author":"Burguete-Cabanas","year":"2018","journal-title":"Allergol Int"},{"issue":"1","key":"10.1016\/j.amjoto.2025.104646_bb0185","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.alit.2016.06.004","article-title":"Long-term safety, efficacy, pharmacokinetics and pharmacodynamics of omalizumab in children with severe uncontrolled asthma","volume":"66","author":"Odajima","year":"2017","journal-title":"Allergol Int"},{"issue":"9","key":"10.1016\/j.amjoto.2025.104646_bb0190","first-page":"1561","article-title":"Omalizumab (anti-IgE) therapy increases blood glucose levels in severe persistent allergic asthma patients with diabetes mellitus: 18 month follow-up","volume":"60","author":"Yalcin","year":"2014","journal-title":"Clin Lab"},{"issue":"5","key":"10.1016\/j.amjoto.2025.104646_bb0195","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.anai.2016.09.006","article-title":"Evaluation of long-term safety and efficacy of omalizumab in elderly patients with uncontrolled allergic asthma","volume":"117","author":"Tat","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"10.1016\/j.amjoto.2025.104646_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2012.01.033","article-title":"Omalizumab and the risk of malignancy: results from a pooled analysis","volume":"129","author":"Busse","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.amjoto.2025.104646_bb0205","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.rmed.2019.05.005","article-title":"Monoclonal antibodies for severe asthma: pharmacokinetic profiles","volume":"153","author":"Matera","year":"2019","journal-title":"Respir Med"},{"issue":"6","key":"10.1016\/j.amjoto.2025.104646_bb0210","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.jaci.2022.08.028","article-title":"Drug allergy: a 2022 practice parameter update","volume":"150","author":"Khan","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.amjoto.2025.104646_bb0215","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jaci.2024.11.005","article-title":"Omalizumab safety concerns","volume":"155","author":"Pongdee","year":"2025","journal-title":"J Allergy Clin Immunol"}],"container-title":["American Journal of Otolaryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196070925000493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196070925000493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T13:31:04Z","timestamp":1762263064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196070925000493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0196070925000493"],"URL":"https:\/\/doi.org\/10.1016\/j.amjoto.2025.104646","relation":{},"ISSN":["0196-0709"],"issn-type":[{"value":"0196-0709","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Research progress of anti-IGE treatment for allergic rhinitis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Otolaryngology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjoto.2025.104646","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104646"}}